20332140

Source:http://linkedlifedata.com/resource/pubmed/id/20332140

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0007131, umls-concept:C0030705, umls-concept:C0034656, umls-concept:C0205179, umls-concept:C0282461, umls-concept:C0677043, umls-concept:C1333355
pubmed:issue	9
pubmed:dateCreated	2010-8-23
pubmed:abstractText	Customized chemotherapy is likely to improve outcome in patients with advanced non-small-cell lung cancer (NSCLC). Excision repair cross-complementation group 1 (ERCC1) is a promising biomarker; however, current evidence is inadequate. Impact of ERCC1 status was evaluated among patients participating in a large randomized chemotherapy trial.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9007735
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin, http://linkedlifedata.com/resource/pubmed/chemical/DNA-Binding Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine, http://linkedlifedata.com/resource/pubmed/chemical/ERCC1 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Endonucleases, http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel, http://linkedlifedata.com/resource/pubmed/chemical/Vinblastine, http://linkedlifedata.com/resource/pubmed/chemical/gemcitabine, http://linkedlifedata.com/resource/pubmed/chemical/vinorelbine
pubmed:status	MEDLINE
pubmed:month	Sep
pubmed:issn	1569-8041
pubmed:author	pubmed-author:SørensenJ BJB, pubmed-author:Santoni-RugiuEE, pubmed-author:VilmarA CAC
pubmed:issnType	Electronic
pubmed:volume	21
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1817-24
pubmed:meshHeading	pubmed-meshheading:20332140-Adenocarcinoma, pubmed-meshheading:20332140-Adolescent, pubmed-meshheading:20332140-Adult, pubmed-meshheading:20332140-Aged, pubmed-meshheading:20332140-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:20332140-Carcinoma, Large Cell, pubmed-meshheading:20332140-Carcinoma, Non-Small-Cell Lung, pubmed-meshheading:20332140-Carcinoma, Squamous Cell, pubmed-meshheading:20332140-Cisplatin, pubmed-meshheading:20332140-DNA-Binding Proteins, pubmed-meshheading:20332140-Deoxycytidine, pubmed-meshheading:20332140-Endonucleases, pubmed-meshheading:20332140-Female, pubmed-meshheading:20332140-Humans, pubmed-meshheading:20332140-Immunoenzyme Techniques, pubmed-meshheading:20332140-Lung Neoplasms, pubmed-meshheading:20332140-Male, pubmed-meshheading:20332140-Middle Aged, pubmed-meshheading:20332140-Neoplasm Staging, pubmed-meshheading:20332140-Paclitaxel, pubmed-meshheading:20332140-Prognosis, pubmed-meshheading:20332140-Survival Rate, pubmed-meshheading:20332140-Vinblastine, pubmed-meshheading:20332140-Young Adult
pubmed:year	2010
pubmed:articleTitle	ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial.
pubmed:affiliation	Department of Oncology, Finsen Centre, Copenhagen, Denmark. adamvilmar@hotmail.com
pubmed:publicationType	Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase III